{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:51:52Z","timestamp":1782143512790,"version":"3.54.5"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No head-to-head trials compare selective interleukin-23 inhibitors in Crohn\u2019s disease (CD), leaving clinicians without direct evidence to guide treatment selection. We aimed to evaluate real-world induction effectiveness of guselkumab in CD and perform propensity score-matched (PSM) comparisons against risankizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective multicentre study included adults with moderate-to-severe CD initiating guselkumab in the United Arab Emirates. The primary outcome was clinical remission at Week 12 (Harvey-Bradshaw Index &amp;lt;5). Full propensity score matching between guselkumab and risankizumab cohorts controlled for 12 covariates including disease phenotype, baseline endoscopic and biochemical activity, surgical history, and current smoking status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-one guselkumab and 60 risankizumab patients were included. In the guselkumab cohort, 71% were advanced therapy-exposed with a median of 2 prior advanced therapies. At Week 12, clinical remission was achieved in 51% (26\/51) and clinical response in 86% (44\/51). Median CRP decreased from 8.5 to 3.0\u2009mg\/L (p\u2009=\u20090.002) and faecal calprotectin from 216 to 80 ug\/g (p\u2009&amp;lt;\u20090.001). Effectiveness was consistent regardless of prior treatment history. On univariable analysis, higher baseline HBI (OR 0.77, p\u2009=\u20090.011), SES-CD (OR 0.87, p\u2009=\u20090.049), and CRP (OR 0.94, p\u2009=\u20090.019) were associated with lower remission likelihood. Maintenance dosing was 100\u2009mg Q8W in 73% and 200\u2009mg Q4W in 27%. PSM analysis demonstrated comparable clinical remission (51% vs 50%, p\u2009&amp;gt;\u20090.9) and clinical response (86% vs 87%, p\u2009=\u20090.87) between guselkumab and risankizumab, with no significant between-group biomarker differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Guselkumab demonstrated robust real-world induction effectiveness comparable to risankizumab across clinical and biochemical outcomes. These findings warrant confirmation in larger, longer-term comparative studies with endoscopic endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag061","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:21:40Z","timestamp":1781695300000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn\u2019s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab"],"prefix":"10.1093","author":[{"given":"Maitha","family":"Al Hosani","sequence":"first","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noorah","family":"Al Hosani","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Nasir","family":"Alzaabi","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam A","family":"Alahmad","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen Mamon","family":"Omar","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille Conde","family":"Oribiana","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas Fouad","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishtiaq","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore Kumar","family":"Chitra Kumar","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Hanif","sequence":"additional","affiliation":[{"name":"Burjeel Institute of Digestive Health, Burjeel Hospital , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Izzeldin Elfatih","family":"Barakat","sequence":"additional","affiliation":[{"name":"Burjeel Institute of Digestive Health, Burjeel Hospital , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Osman Elamin","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Burjeel Institute of Digestive Health, Burjeel Hospital , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City, Pure Health Department of Gastroenterology, , Abu Dhabi,","place":["United Arab Emirates"]},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham , Birmingham,","place":["United Kingdom"]},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,19]]},"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag061\/68560424\/otag061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag061\/68560424\/otag061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:42:24Z","timestamp":1782142944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article\/doi\/10.1093\/crocol\/otag061\/8711825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag061","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"otag061"}}